Levels of interleukin-15 in plasma may predict a favorable outcome of structured treatment interruption in patients with chronic human immunodeficiency virus infection

Massimo Amicosante, Fabrizio Poccia, Cristiana Gioia, Carla Montesano, Simone Topino, Federico Martini, Pasquale Narciso, Leopoldo P. Pucillo, Gianpiero D'Offizi

Research output: Contribution to journalArticlepeer-review

Abstract

Structured treatment interruption (STI) may help to alleviate the problems associated with long-term antiretroviral therapy (ART) in human immunodeficiency virus (HIV)-infected patients. We analyzed the role that baseline levels of cytokines in plasma play as markers of a favorable outcome of STI. Two groups of patients were defined: STI responders and STI nonresponders. STI responders showed a higher baseline concentration of interleukin (IL)-15 in plasma than did STI nonresponders and showed lower levels of tumor necrosis factor (TNF)-α during STI. No differences were observed in levels of IL-2, IL-7, or interferon-α in plasma. Our data show that (1) levels of TNF-α in plasma correlate with HIV viremia and (2) monitoring baseline levels of IL-15 in plasma allows for the identification of a favorable outcome of STI.

Original languageEnglish
Pages (from-to)661-665
Number of pages5
JournalJournal of Infectious Diseases
Volume188
Issue number5
DOIs
Publication statusPublished - Sep 1 2003

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Fingerprint Dive into the research topics of 'Levels of interleukin-15 in plasma may predict a favorable outcome of structured treatment interruption in patients with chronic human immunodeficiency virus infection'. Together they form a unique fingerprint.

Cite this